Y-mAbs Therapeutics, Inc.
YMAB
$4.10
-$0.03-0.73%
NASDAQ
| 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | 12/31/2023 | |
|---|---|---|---|---|---|
| Net Income | 2.97% | 24.34% | -39.52% | -570.95% | 87.25% |
| Total Depreciation and Amortization | -15.70% | -20.92% | -3.77% | -1.24% | -4.17% |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | 100.40% | -17.87% | -15.38% | 94.27% | -20.67% |
| Change in Net Operating Assets | 82.01% | -218.87% | 525.50% | 85.76% | -375.60% |
| Cash from Operations | 82.47% | -3,678.86% | 108.57% | 56.73% | -500.60% |
| Capital Expenditure | -- | -- | -- | -- | -- |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | -- | -- | -- | -- | -- |
| Cash from Investing | -- | -- | -- | -- | -- |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | -- | -- | -- | -- | -- |
| Issuance of Common Stock | 0.72% | -44.31% | 198.98% | 488.00% | -- |
| Repurchase of Common Stock | -- | -- | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -- | -- | -- | -- | -- |
| Cash from Financing | 0.72% | -44.31% | 198.98% | 488.00% | -- |
| Foreign Exchange rate Adjustments | -300.00% | 100.00% | 0.00% | -50.00% | -- |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | 90.83% | -570.78% | 171.23% | 63.60% | -492.97% |